Expression of miRNA-130a in nonsmall cell lung cancer

American Journal of the Medical Sciences

Volumn 340, Issue 5, 2010, Pages 385-388

  Wang, Xiao Chun ^a   Tian, Li Li ^b   Wu, Hai Liang ^c   Jiang, Xiao Yan ^d   Du, Li Qing ^a   Zhang, Heng ^a   Wang, Yue Ying ^a   Wu, Hong Ying ^a   Li, De Guan ^a   She, Yi ^a   Liu, Qing Fen ^a   Fan, Fei Yue ^a   Meng, Ai Min ^a  

^a INSTITUTE OF RADIATION MEDICINE   (China)

^b Beijing Centre for Diseases Prevention and Control   (China)

^c SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

miRNA 130a; NSCLC; Overexpression; Prognosis

Indexed keywords

MICRORNA; MICRORNA 130A; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; SMOKING;

EID: 78349309212     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181e892a0     Document Type: Article

References (18)

1. Ramalingam S, Pawlish K, Gadgeel S, et al. Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol 1998;16:651-7.
2. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13:48-57.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and func-tion. Cell 2004;116:281-97.
4. Kennedy LJ, Barnes A, Happ GM, et al. Extensive interbreed, but minimal intrabreed, variation of DLA class II alleles and haplotypes in dogs. Tissue Antigens 2002;59:194-204.
5. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005;122:6-7.
6. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33.
7. Schmittgen TD, Lee EJ, Jiang J. High-throughput real-time PCR. Methods Mol Biol 2008;429:89-98.
8. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
9. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004;101:11755-60.
10. Gibcus JH, Menkema L, Mastik MF, et al. Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res 2007;13:6257-66.
11. Reshmi SC, Huang X, Schoppy DW, et al. Relationship between FRA11F and 11q13 gene amplification in oral cancer. Genes Chromo-somes Cancer 2007;46:143-54.
12. Cheng CK, Chow LW, Loo WT, et al. The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res 2005;65:8646-54.
13. Zheng SL, Stevens VL, Wiklund F, et al. Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev 2009;18:1815-20.
14. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX andHOXA5. Blood2008;111:1217-26.
15. Garzon R, Fabbri M, Cimmino A, et al. MicroRNA expression and function in cancer. Trends Mol Med 2006;12:580-7.
16. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6.
17. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
18. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of maturemicroRNA-21 andmicroRNA-205 overexpressioninnon-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008; 54:1696-704.